Gene Transfer Trial for Cancer
Phase 1/2
110
about 11 years
18–72
1 site in MD
About this study
This trial is testing a new treatment that involves taking white blood cells from your body, modifying them in the lab with a special gene, and then returning them to you. The goal is to determine if this modified cell therapy is safe and can shrink tumors in people with certain types of cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Anti-KRAS G12V mTCR PBL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Frequency and severity of treatment-related adverse events, Response rate
Oncology